Pharmaceutical bias for Schroder Medical trust

clock

Discovery unit trust, which launches this week, will be biased towards pharmaceuticals and large cap...

Discovery unit trust, which launches this week, will be biased towards pharmaceuticals and large cap stocks. As previously reported in Investment Week, the fund will be managed from New York by Kristine Bryan. The initial portfolio will have around 75% to 80% in pharmaceuticals with around 10% in areas such as biotechnology. Bryan will invest in a universe of approximately 75 companies. The 15 largest healthcare companies make up 85% of the sector's global market cap. Schroders believes companies outside the top 75 in the healthcare sector have poor earnings potential. Bryan said: "The...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

Trustpilot